BR-6002 by Boryung Pharmaceutical for Cardiovascular Disease: Likelihood of Approval
BR-6002, developed by Boryung Pharmaceutical, targets cardiovascular disease, gastric ulcers, and duodenal ulcers via oral administration. Boryung specializes in chronic disease treatments, including hypertension, dyslipidemia, and cancers. GlobalData's analytics assess drug-specific Phase Transition and Likelihood of Approval (PTSR and LoA) scores based on historical data and proprietary algorithms.
Highlighted Terms
Related News
BR-6002, developed by Boryung Pharmaceutical, targets cardiovascular disease, gastric ulcers, and duodenal ulcers via oral administration. Boryung specializes in chronic disease treatments, including hypertension, dyslipidemia, and cancers. GlobalData's analytics assess drug-specific Phase Transition and Likelihood of Approval (PTSR and LoA) scores based on historical data and proprietary algorithms.